Incidence and Description of Autoimmune Cytopenias During Treatment with Ibrutinib for Chronic Lymphocytic Leukemia Autoimmune Cytopenias During Ibrutinib Treatment

Chronic lymphocytic leukemia (CLL) is frequently complicated by secondary autoimmune cytopenias (AIC). Ibrutinib is an irreversible inhibitor of Bruton’s Tyrosine Kinase approved for treatment of relapsed CLL and CLL with del(17p). The effect of ibrutinib treatment on the incidence of AIC is current...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Leukemia
Main Authors: Rogers, Kerry A., Ruppert, Amy S., Bingman, Anissa, Andritsos, Leslie A., Awan, Farrukh T., Blum, Kristie A., Flynn, Joseph M., Jaglowski, Samantha M., Lozanski, Gerard, Maddocks, Kami J., Byrd, John C., Woyach, Jennifer A., Jones, Jeffrey A.
Format: Artigo
Jezik:Inglês
Izdano: 2015
Teme:
Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC4986508/
https://ncbi.nlm.nih.gov/pubmed/26442611
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/leu.2015.273
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki